Last updated: July 31, 2026
Myambutol is the original brand associated with ethambutol hydrochloride, an oral antimycobacterial used mainly as part of combination therapy for tuberculosis. Its commercial position is mature: the active ingredient is off patent, generic products dominate, and no meaningful standalone late-stage clinical program is associated with the brand. Demand should remain stable because ethambutol is embedded in first-line tuberculosis treatment, but pricing and revenue growth are limited by generic competition and public-sector procurement.
What is Myambutol and how is ethambutol used?
Myambutol contains ethambutol hydrochloride, a bacteriostatic antimycobacterial agent that inhibits arabinosyl transferases involved in mycobacterial cell-wall synthesis. It is used with other drugs because monotherapy creates a high risk of resistance.
The main clinical uses are:
| Use |
Role of ethambutol |
| Drug-susceptible pulmonary tuberculosis |
Initial combination regimen with rifampin, isoniazid and pyrazinamide |
| Extrapulmonary tuberculosis |
Included when clinically appropriate |
| Drug-resistant tuberculosis |
Regimen-dependent, based on susceptibility and expert guidance |
| Mycobacterium avium complex infection |
Used in selected multidrug regimens |
| Nontuberculous mycobacterial disease |
Used selectively, particularly in macrolide-based combination treatment |
The standard four-drug regimen for drug-susceptible tuberculosis is commonly abbreviated as HRZE: isoniazid, rifampin, pyrazinamide and ethambutol. The World Health Organization and U.S. Centers for Disease Control and Prevention continue to include ethambutol in recommended initial treatment strategies, subject to resistance patterns and patient-specific factors (World Health Organization, 2022; CDC, 2024).
The most important safety issue is optic toxicity. Baseline and follow-up visual assessment is particularly important in patients receiving prolonged treatment, children who can be monitored reliably, and patients with renal impairment.
What is the current FDA regulatory status of Myambutol?
Myambutol is an established small-molecule product rather than a new FDA development program. Ethambutol hydrochloride tablets are approved in the United States, but commercial supply is primarily generic.
The FDA-approved labeling identifies ethambutol as an oral antimycobacterial for pulmonary tuberculosis. The label includes warnings concerning optic neuritis, visual acuity changes, red-green color discrimination and dose adjustment in renal impairment (FDA, 2023).
FDA status summary
| Regulatory element |
Current position |
| Active ingredient |
Ethambutol hydrochloride |
| Dosage form |
Immediate-release oral tablets |
| Common strengths |
100 mg, 400 mg, 500 mg, 600 mg, 800 mg |
| FDA pathway |
Legacy approved product and abbreviated new drug applications |
| New-drug exclusivity |
Expired |
| Orphan exclusivity |
None associated with the core product |
| Pediatric exclusivity |
No current product-specific exclusivity |
| Biosimilar exposure |
None; ethambutol is a small molecule |
| Primary U.S. supply model |
Generic manufacturers and institutional procurement |
The FDA Orange Book is relevant for determining whether a listed drug has active patent or regulatory exclusivity barriers. Ethambutol products do not have a current exclusivity profile comparable to recently approved branded drugs (FDA, 2024a).
What patents protect Myambutol and ethambutol?
No active composition-of-matter patent is expected to block generic ethambutol in the United States or major international markets. Ethambutol was discovered and commercialized decades ago, placing the original composition patent well beyond its standard patent term.
Patent estate assessment
| Patent category |
Commercial status |
| Original ethambutol composition patent |
Expired |
| Core synthesis patents |
Expired or commercially nonblocking |
| Myambutol brand patents |
No material active exclusivity identified |
| Formulation patents |
No commercially significant blocking estate identified |
| Method-of-use patents |
No active patent barrier to standard tuberculosis use |
| Manufacturing patents |
Potentially relevant to individual suppliers, but not a product-level barrier |
| Orange Book-listed patents |
No current blocking listing expected for generic entry |
The practical intellectual-property risk is therefore low. A manufacturer may hold process know-how, impurity-control methods, crystallization methods or supplier-specific manufacturing protections. Those rights generally do not prevent a qualified competitor from producing ethambutol using a noninfringing process.
Are formulation patents a risk for ethambutol?
Formulation patent risk is limited. Standard ethambutol tablets are mature immediate-release dosage forms with no widely recognized proprietary delivery system. A company developing a novel pediatric dispersible tablet, fixed-dose combination or modified-release formulation could seek formulation or process protection, but that would protect the new dosage form rather than the underlying ethambutol molecule.
The main commercial barrier is regulatory and manufacturing compliance, not patent exclusivity.
When does Myambutol lose exclusivity?
Myambutol lost meaningful market exclusivity decades ago. The active ingredient is available through multiple generic suppliers, and the core molecule is not protected by a current patent term.
This creates several consequences:
- Generic substitution is permitted where national rules allow it.
- Tender purchasers can switch between manufacturers.
- Price competition is strongest in public-health and institutional channels.
- Brand-level pricing power is limited.
- Clinical value remains high even though commercial differentiation is low.
Ethambutol differs from newer tuberculosis drugs such as bedaquiline, pretomanid and delamanid, which have had active patent and regulatory-exclusivity strategies. It also differs from rifapentine, where formulation, regimen and pediatric development can create more commercially relevant protection.
What clinical trials are studying Myambutol and ethambutol?
There is no identifiable late-stage clinical program aimed at re-establishing Myambutol as a proprietary product. Current research involving ethambutol is mostly regimen-based. Researchers include it as a comparator, background drug or component of standard therapy rather than as a standalone investigational product.
Current clinical-trial themes
Drug-susceptible tuberculosis
Ethambutol remains part of the conventional control regimen in trials evaluating shorter treatment durations, alternative rifamycin strategies, host-directed therapies and pediatric regimens. Trial sponsors may remove ethambutol after susceptibility results confirm a low risk of resistance, but it remains important during the initial empiric phase.
Drug-resistant tuberculosis
Ethambutol has a more variable role in resistant disease. Modern trials increasingly evaluate all-oral regimens containing bedaquiline, linezolid, pretomanid, moxifloxacin, levofloxacin, clofazimine or delamanid. Ethambutol may be retained or omitted depending on resistance testing and regimen design.
Pediatric tuberculosis
Pediatric research focuses on child-friendly fixed-dose combinations, dispersible tablets and weight-band dosing. Ethambutol is relevant because it is part of first-line therapy, but the commercial opportunity is more likely to arise from an improved combination product than from a branded ethambutol tablet.
Nontuberculous mycobacterial disease
Ethambutol is used in selected Mycobacterium avium complex regimens, usually with a macrolide and another companion drug. Clinical research in this field is directed toward regimen optimization, inhaled therapies and resistance prevention. The value of ethambutol is indirect because the drug is usually one component of a broader regimen.
Clinical-trial outlook
| Development area |
Outlook for ethambutol |
| Standalone new indication |
Low |
| New branded ethambutol product |
Low |
| Inclusion in tuberculosis regimen trials |
High |
| Pediatric dispersible combinations |
Moderate |
| Nontuberculous mycobacterial regimens |
Moderate |
| Novel delivery technology |
Low to moderate |
| Combination-product development |
Moderate |
ClinicalTrials.gov remains the principal U.S. registry for identifying active interventional studies. Searches for ethambutol generally return studies in which the drug is part of a broader tuberculosis or mycobacterial regimen, not trials designed to generate new exclusivity for Myambutol (National Library of Medicine, 2024).
How strong is the patent estate for Myambutol?
The patent estate is weak from an originator-protection perspective and strong only in the sense that the product has durable clinical utility.
| Factor |
Assessment |
| Composition-of-matter protection |
None remaining |
| Active Orange Book protection |
None of material commercial significance |
| Generic entry risk |
Very high |
| Manufacturing complexity |
Low to moderate |
| Regulatory substitution risk |
High |
| Clinical demand durability |
High |
| Brand pricing power |
Low |
| Lifecycle-management opportunity |
Limited |
The product’s defensibility comes from inclusion in treatment guidelines, established manufacturing capability and procurement relationships. Those are commercial advantages, not patent barriers.
Which companies are challenging Myambutol?
Generic competition is already established rather than prospective. Ethambutol hydrochloride is supplied by multiple generic pharmaceutical companies across the United States, Europe, India, China and other tuberculosis-treatment markets.
The competitive field includes:
- Large generic manufacturers supplying regulated markets.
- Regional manufacturers serving government tenders.
- Public-sector suppliers producing fixed-dose combinations.
- Contract manufacturers supplying national tuberculosis programs.
- Multinational pharmaceutical companies with legacy or regional product registrations.
The most relevant competitors are not necessarily competing brands. They are manufacturers of ethambutol tablets and four-drug fixed-dose combinations.
Are there Paragraph IV challenges involving Myambutol?
Paragraph IV litigation is not a central current issue for ethambutol. The product is an old genericized medicine with no meaningful new patent estate that would normally support a high-value Paragraph IV campaign.
A generic applicant could technically challenge a listed patent if one were relevant to a specific reference product, but the commercial probability of major litigation is low. The more likely market events are supplier changes, abbreviated new drug application approvals, tender awards and manufacturing inspections.
What is the Orange Book status of Myambutol?
The Orange Book does not create a current exclusivity barrier for conventional ethambutol tablets. The relevant products are legacy products and generic equivalents.
Orange Book implications include:
- No remaining new chemical entity exclusivity.
- No meaningful market exclusivity for the original Myambutol brand.
- No expected pediatric exclusivity affecting generic supply.
- No material patent barrier for conventional tablet entry.
- Regulatory review focused on bioequivalence, chemistry, manufacturing and controls.
A product-specific Orange Book review should distinguish between the historical reference product and currently marketed generic applications. The existence of an old reference listing does not imply active brand protection.
What patent litigation affects Myambutol?
No major current U.S. patent litigation is associated with the core ethambutol market. Litigation risk is more likely to arise from:
- Manufacturing-process disputes between suppliers.
- Contract and supply disagreements.
- Product-liability claims involving optic toxicity.
- Regulatory enforcement involving quality, labeling or supply reliability.
- Patent disputes over a new fixed-dose combination or pediatric formulation.
These risks differ from the litigation profile of newer tuberculosis drugs, where composition patents, regimen patents and patent-term extensions can drive settlement negotiations and delayed generic entry.
How does Myambutol compare with newer tuberculosis drugs?
| Drug |
Main role |
Patent position |
Commercial profile |
| Ethambutol |
First-line combination therapy |
Expired |
Low-price generic, high-volume public-health drug |
| Bedaquiline |
Drug-resistant tuberculosis |
Historically active patent estate |
Higher-value branded and generic-transition market |
| Pretomanid |
Drug-resistant tuberculosis combinations |
Active or recently active protection in some markets |
Combination-regimen value |
| Delamanid |
Drug-resistant tuberculosis |
Patent-protected in some jurisdictions historically |
Specialty tuberculosis market |
| Rifapentine |
Tuberculosis prevention and treatment |
More recent product and regimen protection |
Differentiated rifamycin market |
| Linezolid |
Drug-resistant tuberculosis component |
Core molecule off patent |
Generic, higher toxicity and variable pricing |
Ethambutol has lower revenue per treatment course but a broader role in standard therapy. Newer agents have greater revenue concentration and higher patent exposure but serve narrower patient populations.
What is the market outlook for Myambutol?
The standalone Myambutol brand market is small relative to the broader ethambutol market. Publicly available market studies often combine branded and generic ethambutol, tuberculosis therapeutics or broader antimycobacterial products, producing inconsistent revenue estimates. There is no single authoritative global revenue series for Myambutol alone.
Demand drivers
- Global tuberculosis incidence.
- National treatment-program enrollment.
- Continued use of HRZE therapy.
- Expansion of tuberculosis diagnosis and treatment in high-burden countries.
- Procurement of fixed-dose combinations.
- Pediatric treatment programs.
- Ethambutol use in selected nontuberculous mycobacterial infections.
Market constraints
- Generic price erosion.
- Government tender concentration.
- Limited brand differentiation.
- Low treatment-course pricing in high-burden markets.
- Substitution by fixed-dose combinations.
- Declining use when susceptibility testing supports narrower therapy.
- Manufacturing and supply-chain volatility.
Five-year projection
The most defensible forecast is a stable-to-low-growth outlook for global ethambutol volume and a flat-to-declining outlook for branded revenue.
| Segment |
Five-year volume outlook |
Five-year pricing outlook |
Revenue outlook |
| Standalone branded Myambutol |
Declining |
Declining or flat |
Declining |
| Generic ethambutol tablets |
Stable to modest growth |
Downward pressure |
Flat to modest growth |
| Fixed-dose combinations containing ethambutol |
Modest growth |
Competitive |
Modest growth |
| Pediatric dispersible combinations |
Faster growth from a small base |
More resilient |
Modest growth |
| Nontuberculous mycobacterial use |
Selective growth |
Variable |
Small positive contribution |
In a base case, global unit demand can grow at a low single-digit rate as tuberculosis programs expand, while average selling prices decline. The result is likely low-single-digit revenue growth for the broad generic ethambutol category and negative growth for the legacy Myambutol brand.
A stronger upside case requires increased tuberculosis diagnosis, improved treatment access and greater use of dispersible fixed-dose combinations. A downside case would involve tender price compression, supplier exits or substitution within resistant-disease regimens.
What generic launch scenarios exist for ethambutol?
Because the core molecule is off patent, generic launch risk is already realized rather than pending.
Scenario 1: Additional tablet suppliers
New suppliers can enter through standard generic approval pathways if they demonstrate pharmaceutical equivalence, bioequivalence and compliant manufacturing. This would increase price pressure.
Scenario 2: Fixed-dose combination expansion
The most commercially relevant product development path is a four-drug or pediatric combination containing ethambutol. Competition would focus on formulation, dispersibility, dose flexibility, palatability and procurement qualification.
Scenario 3: Supplier consolidation
Regulatory inspections, quality failures or low margins could reduce the number of active suppliers. Consolidation could temporarily improve pricing but would increase shortage risk.
Scenario 4: Guideline-driven regimen change
If treatment guidelines reduce ethambutol use in a defined subgroup after rapid molecular susceptibility testing, unit demand could decline in that segment. Broad first-line use would continue.
What manufacturing and IP barriers affect ethambutol?
Ethambutol is not among the most technically difficult small molecules to manufacture, but commercial supply requires control of:
- Active pharmaceutical ingredient purity.
- Stereochemical composition.
- Residual solvents and impurities.
- Tablet content uniformity.
- Stability under heat and humidity.
- Reliable supply of multiple tablet strengths.
- Bioequivalence across dosage strengths.
- Quality documentation for public procurement.
- GMP compliance in inspection-heavy markets.
Manufacturing know-how can create a supplier advantage, especially for fixed-dose combinations and dispersible formulations. It does not provide the same market exclusion as a valid composition patent.
What licensing deals involve Myambutol?
No recent high-value licensing transaction is central to the Myambutol market. The original brand’s commercial history involved legacy pharmaceutical ownership and regional commercialization arrangements, but current value is concentrated in generic registrations, supply contracts and public-health procurement.
Potential licensing activity would be more likely for:
- Pediatric fixed-dose combinations.
- Regional marketing rights.
- Government-supply agreements.
- Contract manufacturing.
- New formulations designed to improve adherence.
The absence of major licensing activity reflects the low-margin, mature nature of conventional ethambutol tablets.
What revenue exposure does Myambutol create?
For a diversified pharmaceutical company, direct Myambutol revenue exposure is limited unless the company has a large tuberculosis portfolio or a government-supply contract. The larger exposure is indirect:
- Ethambutol shortages can affect complete HRZE regimen supply.
- A failed supplier can disrupt national procurement.
- Fixed-dose combination tenders can shift volume rapidly.
- Quality recalls can create replacement demand for competitors.
- Changes in tuberculosis guidelines can alter regimen composition.
Ethambutol is strategically important to tuberculosis treatment but generally not a major earnings driver for diversified pharmaceutical companies.
Key Takeaways
- Myambutol is the legacy brand associated with ethambutol hydrochloride.
- The active ingredient is off patent, and generic competition is established.
- No meaningful current Orange Book exclusivity or blocking patent estate protects conventional ethambutol tablets.
- Clinical research uses ethambutol mainly as part of tuberculosis and nontuberculous mycobacterial regimens.
- Standalone branded revenue should continue to decline.
- Generic ethambutol volume should remain stable or grow modestly with tuberculosis treatment demand.
- Fixed-dose combinations and pediatric dispersible products offer the clearest commercial opportunities.
- The principal risks are price erosion, tender concentration, supplier quality and shortages, not Paragraph IV litigation.
- Ethambutol has durable clinical demand but limited patent-based commercial defensibility.
Frequently Asked Questions
Is Myambutol still marketed in the United States?
Ethambutol remains available in the United States, primarily through generic products. The original Myambutol brand has limited commercial relevance compared with generic ethambutol hydrochloride tablets.
Is ethambutol a biologic or biosimilar product?
No. Ethambutol is a conventional synthetic small molecule. Biosimilar rules do not apply. Generic entry uses abbreviated drug-approval pathways based on pharmaceutical equivalence and bioequivalence.
Does ethambutol require a new clinical trial for generic approval?
A conventional generic applicant typically does not repeat the originator’s full efficacy program. Approval generally depends on demonstrating equivalence, quality and manufacturing compliance, subject to FDA requirements for the specific application.
Can ethambutol be used alone to treat tuberculosis?
No. Ethambutol should not be used as tuberculosis monotherapy because resistance can develop rapidly. It is used with other active antimycobacterial agents under an appropriate treatment regimen.
Which product has greater commercial potential: ethambutol tablets or fixed-dose combinations?
Fixed-dose combinations have greater differentiation potential. Conventional ethambutol tablets are mature generic products, while pediatric dispersible and multi-drug formulations can compete on usability, procurement qualification and adherence.
References
-
Centers for Disease Control and Prevention. (2024). Treatment for drug-susceptible tuberculosis disease. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2023). Ethambutol hydrochloride tablets: Prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
National Library of Medicine. (2024). ClinicalTrials.gov: Ethambutol clinical studies. U.S. National Institutes of Health.
-
World Health Organization. (2022). WHO consolidated guidelines on tuberculosis: Module 4, treatment: Drug-susceptible tuberculosis treatment. World Health Organization.
